Continuation of Tyrosine Kinase Inhibitor is Associated with Survival Benefit in NSCLC Patients with Exon 19 Deletion after Solitary Progression

Introduction: The benefit and selection criteria of continuing tyrosine kinase inhibitor (TKI) after secondary resistance in non-small cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) mutation remain largely unknown. This study was designed to investigate the role and predicti...

Descripción completa

Detalles Bibliográficos
Autores principales: Na, Feifei, Zhang, Jie, Deng, Lei, Zhou, Xiaojuan, Zhou, Lin, Zou, Bingwen, Yu, Min, Li, Yanying, Xue, Jianxin, Liu, Yongmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5688921/
https://www.ncbi.nlm.nih.gov/pubmed/29151955
http://dx.doi.org/10.7150/jca.20017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5688921/
https://www.ncbi.nlm.nih.gov/pubmed/29151955
http://dx.doi.org/10.7150/jca.20017

Ejemplares similares